Roche to work with NHS on digital pathology services

Healthcare company Roche Diagnostics will work together with the government, the NHS and academia to create a new digital tissue laboratory.
The partnership, announced as part of the government’s Life Sciences sector deal, could transform the way conditions such as cancer are diagnosed.

The Life Sciences sector deal details that the organisations are working towards the implementing mainstream digital pathology services across the NHS. The investment could see the NHS implementing new approaches to cancer testing such as whole slide scanners, management software and image analysis algorithms.

The availability of electronic information could open up the possibility for new treatments as well as the development of artificial intelligence algorithms min pathology diagnosis. The greater efficiency in tissue pathology services could benefit patient care and help deliver faster and more accurate test results across the NHS.

Commenting on the announcement, Geoff Twist, managing director of Roche Diagnostics UK & Ireland, said: “Roche Diagnostics is proud to be working with the Government at what is an incredibly exciting time for the future of our NHS. For a number of years, Roche has led the way in advances in medicines and diagnostics and we take great pride in our collaborative working relationship with the Government and NHS to deliver the best possible solutions in patient care. Today’s announcement from the government  could help transform tissue pathology services and pave the way for the UK to create a new global industry with Artificial Intelligence and Digital Pathology at its forefront. We are committed to helping the Government moving forward.”


Reece Armstrong is a reporter for Digital Health Age. Coming from the North East of England, Reece has an MA in Media & Journalism and a BA in Popular & Contemporary Music from Newcastle University. Reach him on Twitter or email via:

'Roche to work with NHS on digital pathology services' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2018 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions